Stock Screener
Stock Research
Market Indexes
Precious Metals
Energy
Commodities
Exchange Rates
Interest Rates
Futures
Economy
Global Metrics

Amicus Therapeutics Net Income 2007-2019 | FOLD

Amicus Therapeutics net income from 2007 to 2019. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
Amicus Therapeutics Annual Net Income
(Millions of US $)
2018 $-349
2017 $-284
2016 $-200
2015 $-132
2014 $-69
2013 $-60
2012 $-49
2011 $-44
2010 $-55
2009 $-7
2008 $-39
2007 $-42
2006 $-42
2005 $-20
Amicus Therapeutics Quarterly Net Income
(Millions of US $)
Q1 2019 $-120
Q4 2018 $-78
Q3 2018 $-159
Q2 2018 $-62
Q1 2018 $-50
Q4 2017 $-69
Q3 2017 $-112
Q2 2017 $-48
Q1 2017 $-55
Q4 2016 $-59
Q3 2016 $-47
Q2 2016 $-51
Q1 2016 $-44
Q4 2015 $-43
Q3 2015 $-38
Q2 2015 $-27
Q1 2015 $-24
Q4 2014 $-21
Q3 2014 $-17
Q2 2014 $-15
Q1 2014 $-16
Q4 2013 $-12
Q3 2013 $-15
Q2 2013 $-15
Q1 2013 $-17
Q4 2012 $-10
Q3 2012 $-16
Q2 2012 $-9
Q1 2012 $-13
Q4 2011 $-9
Q3 2011 $-10
Q2 2011 $-13
Q1 2011 $-13
Q4 2010 $-15
Q3 2010 $-15
Q2 2010 $-11
Q1 2010 $-13
Q4 2009 $33
Q3 2009 $-13
Q2 2009 $-14
Q1 2009 $-12
Q4 2008 $-14
Q3 2008 $-8
Q2 2008 $-9
Q1 2008 $-8
Q4 2007 $-12
Q3 2007 $-10
Q2 2007 $-10
Q1 2007 $-10
Q3 2006 $-12
Q2 2006 $-28
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $2.888B $0.091B
AMICUS THERAPEUTICS is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilizeproteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus has completed Phase 2 clinical trials of Amigal(TM) for the treatment of Fabry disease and is conducting Phase 2 clinical trials of Plicera(TM) for the treatment of Gaucher disease.
Stock Name Country Market Cap PE Ratio
Amgen (AMGN) United States $107.422B 12.15
Gilead Sciences (GILD) United States $86.782B 10.54
Celgene (CELG) United States $64.715B 10.96
Biogen (BIIB) United States $45.297B 8.60
Vertex Pharmaceuticals (VRTX) United States $45.172B 54.60
Illumina (ILMN) United States $44.437B 51.50
CSL (CSLLY) Australia $35.310B 0.00
Regeneron Pharmaceuticals (REGN) United States $32.586B 15.32
Actelion (ALIOF) Switzerland $29.891B 0.00
Alexion Pharmaceuticals (ALXN) United States $27.590B 15.61
Incyte (INCY) United States $17.453B 70.77
BioMarin Pharmaceutical (BMRN) United States $15.040B 0.00
Exact Sciences (EXAS) United States $15.005B 0.00
SINO PHARMACEUT (SBMFF) China $14.407B 0.00
Sarepta Therapeutics (SRPT) United States $11.635B 0.00
Genmab (GNMSF) Denmark $11.067B 56.26
Array BioPharma (ARRY) United States $10.358B 0.00
Seattle Genetics (SGEN) United States $10.323B 0.00
Bio-Rad Laboratories (BIO.B) United States $9.283B 49.21
QIAGEN (QGEN) Netherlands $9.032B 29.67
Galapagos (GLPG) Belgium $8.749B 0.00
Guardant Health (GH) United States $8.099B 0.00
Bio-Techne Corp (TECH) United States $7.974B 54.41
Alnylam Pharmaceuticals (ALNY) United States $7.755B 0.00
Bluebird Bio (BLUE) United States $7.483B 0.00
Amarin (AMRN) Ireland $7.232B 0.00
Exelixis (EXEL) United States $6.464B 16.48
BeiGene (BGNE) Cayman Islands $5.733B 0.00
Ascendis Pharma (ASND) Denmark $4.717B 0.00
Moderna (MRNA) United States $4.711B 0.00
Blueprint Medicines (BPMC) United States $4.686B 0.00
ARGENX SE-ADR (ARGX) Netherlands $4.616B 0.00
Horizon Pharma Public (HZNP) Ireland $4.348B 11.20
Repligen (RGEN) United States $4.059B 101.12
ACADIA Pharmaceuticals (ACAD) United States $3.852B 0.00
Mirati Therapeutics (MRTX) United States $3.805B 0.00
Spark Therapeutics (ONCE) United States $3.765B 0.00
China Biologic Products (CBPO) China $3.689B 23.43
Alkermes (ALKS) Ireland $3.662B 0.00
Ultragenyx Pharmaceutical (RARE) United States $3.369B 0.00
MorphoSys AG (MOR) Germany $3.287B 0.00
Arena Pharmaceuticals (ARNA) United States $3.077B 6.25
Immunomedics (IMMU) United States $2.724B 0.00
Medicines (MDCO) United States $2.713B 0.00
UniQure (QURE) Netherlands $2.633B 0.00
CRISPR Therapeutics AG (CRSP) Switzerland $2.607B 0.00
Reata Pharmaceuticals (RETA) United States $2.582B 0.00
Halozyme Therapeutics (HALO) United States $2.461B 0.00
Nabriva Therapeutics AG (NBRV) Ireland $2.328B 0.00
MyoKardia (MYOK) United States $2.314B 0.00
Ligand Pharmaceuticals (LGND) United States $2.291B 18.98
Emergent Biosolutions (EBS) United States $2.238B 19.44
Akcea Therapeutics (AKCA) United States $2.178B 0.00
Acceleron Pharma (XLRN) United States $2.159B 0.00
NeoGenomics (NEO) United States $2.133B 139.63
Genomic Health (GHDX) United States $2.121B 45.04
Zai Lab (ZLAB) China $2.116B 0.00
Intercept Pharmaceuticals (ICPT) United States $2.064B 0.00
Denali Therapeutics (DNLI) United States $1.970B 0.00
Myriad Genetics (MYGN) United States $1.912B 19.02
REGENXBIO (RGNX) United States $1.759B 0.00
Insmed (INSM) United States $1.725B 0.00
Cambrex (CBM) United States $1.523B 19.25
AnaptysBio (ANAB) United States $1.504B 0.00
Fate Therapeutics (FATE) United States $1.443B 0.00
Innoviva (INVA) United States $1.428B 3.95
RA PHARMCTL INC (RARX) United States $1.404B 0.00
Sangamo Therapeutics (SGMO) United States $1.384B 0.00
Athenex (ATNX) United States $1.341B 0.00
Alector (ALEC) United States $1.309B 0.00
Coherus BioSciences (CHRS) United States $1.308B 0.00
Editas Medicine (EDIT) United States $1.245B 0.00
Epizyme (EPZM) United States $1.240B 0.00
Orchard Therapeutics (ORTX) United Kingdom $1.188B 0.00
Momenta Pharmaceuticals (MNTA) United States $1.050B 0.00
Codexis (CDXS) United States $1.022B 0.00
Cara Therapeutics (CARA) United States $1.010B 0.00
Adverum Biotechnologies (ADVM) United States $0.986B 0.00
ANI Pharmaceuticals (ANIP) United States $0.973B 17.26
Dicerna Pharmaceuticals (DRNA) United States $0.970B 0.00
Alder BioPharmaceuticals (ALDR) United States $0.950B 0.00
Principia Biopharma (PRNB) United States $0.945B 0.00
Twist Bioscience (TWST) United States $0.942B 0.00
Zymeworks (ZYME) Canada $0.936B 0.00
WAVE Life Sciences (WVE) Singapore $0.925B 0.00
ZIOPHARM Oncology Inc (ZIOP) United States $0.924B 0.00
Retrophin (RTRX) United States $0.879B 0.00
Vericel (VCEL) United States $0.861B 0.00
BAVARIAN NORDIC (BVNRY) Denmark $0.856B 0.00
Arvinas (ARVN) United States $0.805B 0.00
Intellia Therapeutics (NTLA) United States $0.767B 0.00
Vanda Pharmaceuticals (VNDA) United States $0.719B 33.92
Precision BioSciences (DTIL) United States $0.693B 0.00
Clovis Oncology (CLVS) United States $0.687B 0.00
Zealand Pharma (ZLDPF) Denmark $0.683B 0.00
Zealand Pharma (ZEAL) Denmark $0.676B 7.90
Cellectis S.A (CLLS) France $0.654B 0.00
Autolus Therapeutics (AUTL) United Kingdom $0.646B 0.00
Cytokineticsorporated (CYTK) United States $0.639B 0.00
Lexicon Pharmaceuticals (LXRX) United States $0.631B 0.00
Intra-Cellular Therapies (ITCI) United States $0.630B 0.00
Heska (HSKA) United States $0.629B 64.40
DBV Technologies S.A (DBVT) France $0.621B 0.00
OXFORD BIOMEDCL (OXBDF) United Kingdom $0.575B 0.00
Anika Therapeutics (ANIK) United States $0.573B 19.58
MiMedx (MDXG) United States $0.561B 0.00
Revance Therapeutics (RVNC) United States $0.552B 0.00
Stemline Therapeutics (STML) United States $0.551B 0.00
CytomX Therapeutics (CTMX) United States $0.534B 0.00
Pharming Group (PHGUF) Netherlands $0.521B 0.00
Mesoblast (MESO) Australia $0.503B 0.00
PHARMA MAR SA (PHMMF) Spain $0.459B 0.00
UROGEN PHARMA (URGN) United States $0.446B 0.00
Basilea Pharmaceutica AG (BPMUF) Switzerland $0.442B 0.00
Puma Biotechnology (PBYI) United States $0.433B 0.00
Gritstone Oncology (GRTS) United States $0.395B 0.00
Prothena (PRTA) Ireland $0.386B 0.00
Biofrontera AG (BFRA) Germany $0.385B 0.00
Scholar Rock Holding (SRRK) United States $0.376B 0.00
PDL BioPharma (PDLI) United States $0.373B 8.91
AC Immune SA (ACIU) Switzerland $0.372B 23.96
Arcus Biosciences (RCUS) United States $0.371B 0.00
Sinovac Biotech (SVA) China $0.371B 0.00
Adaptimmune Therapeutics (ADAP) United Kingdom $0.366B 0.00
Bellus Health (BLUSF) Canada $0.359B 0.00
Merus (MRUS) Netherlands $0.358B 0.00
Avid Bioservices (CDMO) United States $0.352B 0.00
BioDelivery Sciences (BDSI) United States $0.350B 0.00
Albireo Pharma (ALBO) United States $0.347B 0.00
Achillion Pharmaceuticals (ACHN) United States $0.343B 0.00
Prometic Life Sciences (PFSCD) Canada $0.341B 0.00
Agenus (AGEN) United States $0.341B 0.00
Senesco Technologies (ELOX) United States $0.338B 0.00
Starpharma Holdings (SPHRY) Australia $0.337B 0.00
Theratechnologies (THERF) Canada $0.330B 0.00
Kadmon Holdings (KDMN) United States $0.321B 0.00
Syros Pharmaceuticals (SYRS) United States $0.319B 0.00
Acorda Therapeutics (ACOR) United States $0.316B 5.56
AMAG Pharmaceuticals (AMAG) United States $0.312B 0.00
Sorrento Therapeutics (SRNE) United States $0.308B 0.00
Protagonist Therapeutics (PTGX) United States $0.308B 0.00
Kindred Biosciences (KIN) United States $0.305B 0.00
Inovio Pharmaceuticals (INO) United States $0.290B 0.00
Xenon Pharmaceuticals (XENE) Canada $0.271B 0.00
Cellular Biomedicine (CBMG) United States $0.266B 0.00
PHASEBIO PHARMA (PHAS) United States $0.263B 0.00
Dynavax Technologies (DVAX) United States $0.263B 0.00
Sutro Biopharma (STRO) United States $0.262B 0.00
ChromaDex (CDXC) United States $0.250B 0.00
Syndax Pharmaceuticals (SNDX) United States $0.243B 0.00
Kamada (KMDA) Israel $0.236B 9.16
Athersys (ATHX) United States $0.234B 0.00
ADMA Biologics Inc (ADMA) United States $0.233B 0.00
Cel-Sci (CVM) United States $0.231B 0.00
Geron (GERN) United States $0.229B 0.00
Palatin Technologies (PTN) United States $0.226B 0.00
Pieris Pharmaceuticals (PIRS) United States $0.210B 0.00
Synlogic (SYBX) United States $0.210B 0.00
Cerecor (CERC) United States $0.208B 0.00
Abeona Therapeutics (ABEO) United States $0.207B 0.00
MannKind (MNKD) United States $0.205B 0.00
CorMedix Inc (CRMD) United States $0.204B 0.00
Five Prime Therapeutics (FPRX) United States $0.202B 0.00
Pfenex (PFNX) United States $0.197B 0.00
Affimed (AFMD) Germany $0.197B 0.00
Aeglea BioTherapeutics (AGLE) United States $0.196B 0.00
POXEL SA FRANCE (PXXLF) $0.194B 0.00
Mersana Therapeutics (MRSN) United States $0.190B 0.00
Spero Therapeutics (SPRO) United States $0.188B 0.00
OSMOTICA PHARM (OSMT) United States $0.187B 0.00
Enzo Biochem (ENZ) United States $0.185B 0.00
Arsanis (XFOR) United States $0.184B 0.00
BioTime (BTX) United States $0.180B 12.00
Compugen (CGEN) Israel $0.177B 0.00
Newron Pharmaceuticals SpA (NWPHF) $0.165B 0.00
Nicox SA (NICXF) France $0.163B 0.00
EYEPOINT PHARMACEUTICALS, INC (EYPT) United States $0.160B 0.00
XOMA (XOMA) United States $0.159B 0.00
Strongbridge Biopharma (SBBP) United States $0.155B 8.94
Liquidia Technologies (LQDA) United States $0.146B 0.00
Cue Biopharma (CUE) United States $0.144B 0.00
OvaScience (MLND) United States $0.144B 0.00
Celyad SA (CYAD) Belgium $0.140B 0.00
Adocia (ADOCY) France $0.140B 0.00
TOCAGEN INC (TOCA) United States $0.138B 0.00
Dyadic (DYAI) United States $0.138B 0.00
Northwest Biotherapeutics (NWBO) United States $0.133B 0.00
Arbutus Biopharma (ABUS) Canada $0.133B 0.00
Aptinyx (APTX) United States $0.128B 0.00
Aduro Biotech (ADRO) United States $0.122B 0.00
Menlo Therapeutics (MNLO) United States $0.119B 0.00
Paratek Pharmaceuticals (PRTK) United States $0.119B 0.00
AVEO Pharmaceuticals (AVEO) United States $0.117B 0.00
Alcobra (ARCT) United States $0.117B 0.00
Seres Therapeutics (MCRB) United States $0.115B 0.00
Novavax (NVAX) United States $0.111B 0.00
NantKwest (NK) United States $0.111B 0.00
Nymox Pharmaceutical (NYMX) Canada $0.110B 0.00
Verastem (VSTM) United States $0.108B 0.00
ASLAN Pharmaceuticals (ASLN) Singapore $0.103B 0.00
Catalyst Biosciences (CBIO) United States $0.100B 0.00
Fortress Biotech (FBIO) United States $0.099B 0.00
Trevena (TRVN) United States $0.098B 0.00
Checkpoint Therapeutics (CKPT) United States $0.098B 0.00
SESEN BIO, INC (SESN) United States $0.095B 0.00
Catabasis Pharmaceuticals (CATB) United States $0.086B 0.00
AquaBounty Technologies (AQB) United States $0.085B 0.00
ANIXA BIOSCIENCES INC (ANIX) United States $0.084B 0.00
Aridis Pharmaceuticals (ARDS) United States $0.084B 0.00
Curis (CRIS) United States $0.082B 0.00
VBI Vaccines (VBIV) United States $0.080B 0.00
Pluristem Therapeutics (PSTI) Israel $0.078B 0.00
Spring Bank Pharmaceuticals (SBPH) United States $0.078B 0.00
Selecta Biosciences (SELB) United States $0.077B 0.00
Merrimack Pharmaceuticals (MACK) United States $0.075B 0.00
Idera Pharmaceuticals (IDRA) United States $0.070B 0.00
Applied Genetic Technologies (AGTC) United States $0.069B 38.00
VTv Therapeutics (VTVT) United States $0.069B 0.00
Unum Therapeutics (UMRX) United States $0.069B 0.00
Orgenesis (ORGS) United States $0.067B 0.00
Signal Genetics (MGEN) United States $0.065B 0.00
Organovo Holdings (ONVO) United States $0.065B 0.00
ARAVIVE, INC (ARAV) United States $0.064B 0.00
Sunesis Pharmaceuticals (SNSS) United States $0.062B 0.00
Alimera Sciences (ALIM) United States $0.062B 0.00
Protalix BioTherapeutics (PLX) Israel $0.061B 0.00
Invo BioScience (IVOB) United States $0.059B 0.00
Antibe Therapeutics (ATBPF) Canada $0.059B 0.00
Prima BioMed (IMMP) Australia $0.058B 0.00
NewLink Genetics (NLNK) United States $0.054B 0.00
Oncobiologics (OTLK) United States $0.052B 0.00
DiaMedica Therapeutics (DMAC) United States $0.051B 0.00
Vascular Biogenics (VBLT) Israel $0.051B 0.00
Proteostasis Therapeutics (PTI) United States $0.050B 0.00